A detailed history of Parkside Financial Bank & Trust transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Parkside Financial Bank & Trust holds 56 shares of ALNY stock, worth $13,007. This represents 0.0% of its overall portfolio holdings.

Number of Shares
56
Previous 41 36.59%
Holding current value
$13,007
Previous $9,000 66.67%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$233.81 - $287.01 $3,507 - $4,305
15 Added 36.59%
56 $15,000
Q2 2024

Aug 05, 2024

BUY
$143.31 - $247.0 $716 - $1,235
5 Added 13.89%
41 $9,000
Q1 2024

May 01, 2024

SELL
$146.51 - $198.2 $293 - $396
-2 Reduced 5.26%
36 $5,000
Q4 2023

Feb 01, 2024

BUY
$151.41 - $196.57 $1,968 - $2,555
13 Added 52.0%
38 $7,000
Q3 2023

Nov 13, 2023

BUY
$170.77 - $211.65 $341 - $423
2 Added 8.7%
25 $4,000
Q2 2023

Aug 15, 2023

BUY
$185.01 - $212.05 $555 - $636
3 Added 15.0%
23 $4,000
Q1 2023

May 04, 2023

SELL
$182.66 - $235.53 $365 - $471
-2 Reduced 9.09%
20 $4,000
Q3 2022

Nov 01, 2022

BUY
$138.54 - $232.0 $277 - $464
2 Added 10.0%
22 $5,000
Q2 2022

Jul 13, 2022

SELL
$120.42 - $169.29 $1,324 - $1,862
-11 Reduced 35.48%
20 $2,000
Q1 2022

May 13, 2022

SELL
$127.18 - $173.91 $508 - $695
-4 Reduced 11.43%
31 $5,000
Q4 2021

Feb 14, 2022

BUY
$159.56 - $209.29 $638 - $837
4 Added 12.9%
35 $6,000
Q3 2021

Oct 29, 2021

BUY
$169.75 - $207.73 $848 - $1,038
5 Added 19.23%
31 $6,000
Q2 2021

Aug 06, 2021

BUY
$128.63 - $176.89 $771 - $1,061
6 Added 30.0%
26 $4,000
Q4 2020

Feb 09, 2021

BUY
$122.97 - $147.0 $2,459 - $2,940
20 New
20 $3,000
Q4 2019

Jan 30, 2020

SELL
$74.51 - $124.23 $968 - $1,614
-13 Closed
0 $0
Q3 2019

Nov 05, 2019

BUY
$70.9 - $87.82 $921 - $1,141
13 New
13 $1,000

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $28.6B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Parkside Financial Bank & Trust Portfolio

Follow Parkside Financial Bank & Trust and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parkside Financial Bank & Trust, based on Form 13F filings with the SEC.

News

Stay updated on Parkside Financial Bank & Trust with notifications on news.